1. [Treatment of psoriasis vulgaris]. Med Monatsschr. 1959; 13:103–4.
2. , , Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities. Br J Dermatol 2004; 150:741–746.
3. , Fumaric acid esters, their place in the treatment of psoriasis. Br J Dermatol 2004; 150:630–2.
4. , , , et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol 1994; 30:977–81.
5. , , , van de , , Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur J Immunol 1996; 26:2067–74.
6. , , , et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol 2006; 13:604–10.
7. , , , Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol 2003; 121:1383–8.
8. , , , Antiproliferative and cytotoxic profiles of antipsoriatic fumaric acid derivatives in keratinocyte cultures. Eur J Pharmacol 1994; 270:79–87.
9. , , , , , The antipsoriatic dimethyl-fumarate suppresses interferon-gamma -induced ICAM-1 and HLA-DR expression on hyperproliferative keratinocytes. Quantification by a culture plate-directed APAAP-ELISA technique. Eur J Dermatol 1998; 8:29–32.
10. , , , et al. Methyl hydrogen fumarate inhibits acute and chronic rejection in rat kidney transplantation models. Transpl Proc 2001; 33:545–6.
11. , , , et al. Fumaric acid esters are potent immunosuppressants: inhibition of acute and chronic rejection in rat kidney transplantation models by methyl hydrogen fumarate. Arch Dermatol Res 2002; 294:399–404.
12. , , , et al. Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells. J Immunol 2002; 168:4781–7.
13. , , , et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011; 134:678–92.
14. , , , et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008; 372:1463–72.
15. , , , , , The antipsoriatic drug dimethylfumarate strongly suppresses chemokine production in human keratinocytes and peripheral blood mononuclear cells. Br J Dermatol 2001; 144:1114–20.
16. , , Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006; 129:1953–71.
17. , , , , Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol 2006; 145:101–7.
18. , , , , Diffusion tensor magnetic resonance imaging in multiple sclerosis. Neurology 2001; 56:304–11.
19. , , , , , , et al. Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. J Neurol 2004; 251:407–13.
20. , , , et al. BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis. J Neurol 2010 Epub Oct 21.